Kala Bio, INC. 8-K Filing

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share KALA The Nasdaq

Filing Documents

• kalabio_8k.htm (8-K) — 27KB
• 0001829126-25-010330.txt ( ) — 187KB
• kala-20251219.xsd (EX-101.SCH) — 3KB
• kala-20251219_lab.xml (EX-101.LAB) — 33KB
• kala-20251219_pre.xml (EX-101.PRE) — 22KB
• kalabio_8k_htm.xml (XML) — 3KB

01. Changes in Registrant's Certifying Accountant

Item 4.01. Changes in Registrant's Certifying Accountant As previously disclosed in the Company's Current Report on Form 8-K filed on December 16, 2025, the audit committee of the Company's Board of Directors approved the dismissal of Deloitte & Touche LLP as the Company's independent registered public accounting firm. On December 19, 2025, the Audit Committee approved the engagement of HTL International, LLC ("HTL") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. During the Company's two most recent fiscal years and the subsequent interim period through December 19, 2025, neither the Company, nor anyone on its behalf, consulted HTL regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements, and neither a written report nor oral advice was provided to the Company that HTL concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K, or (iii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable event of the type described in Item 304(a)(1)(v) of Regulation S-K.

02

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As disclosed in the Company's Preliminary Proxy Andrew I. Koven, C. Daniel Myers, Todd Bazmore, Mark Iwicki, and Howard B. Rosen tendered on December 19, 2025 a conditional resignation from their positions as director effective immediately after the Company's 2025 Annual Meeting if stockholder approval is obtained at such 2025 Annual Meeting for (i) the issuance of shares of the Company's common stock upon conversion of certain preferred stock, as described in Proposal 4 of the Company's preliminary proxy materials, and (ii) an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of common stock, as described in Proposal 5 of the Company's preliminary proxy materials. If both proposals are approved, the resignations will become effective immediately following the 2025 Annual Meeting; if both proposals are not approved, the resignations will not take effect. David Lazar is expected to remain a Class II director in either case after the 2025 Annual Meeting. The resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALA BIO, INC. Date: December 29, 2025 By: /s/ David Lazar David Lazar Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR